{"id":"W4322771176","doi":"10.1158/1538-7445.sabcs22-ot3-26-01","title":"Abstract OT3-26-01: CCTG MA40: DOUBLE-BLIND PLACEBO CONTROLLED PHASE III TRIAL OF FULVESTRANT AND IPATASERTIB FOR ADVANCED HER-2 NEGATIVE AND ESTROGEN RECEPTOR POSITIVE (ER+) BREAST CANCER POST FIRST LINE CDK 4/6 AND AROMATASE INHIBITOR THERAPY (FINER)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; University Health Network; Vancouver Hospital and Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Breast cancer; Anastrozole; Placebo; PTEN; Exemestane; Cancer; Palbociclib; Tolerability; Estrogen receptor; Metastatic breast cancer; PI3K/AKT/mTOR pathway; Adverse effect; Tamoxifen; Pathology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00103863,0.0005189343,0.001299593,0.0004738345,0.0004126602,0.0000877385,0.0001829826,0.0002261297,0.0002117197],"category_scores_gemma":[0.0001857018,0.0004187766,0.000152081,0.0006965728,0.0009982915,0.0003946955,0.0001247989,0.0006096154,0.000004275106],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002903853,"about_ca_system_score_gemma":0.0008123507,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00160124,"about_ca_topic_score_gemma":0.0005229578,"domain_scores_codex":[0.9963464,0.0001392835,0.0007930709,0.0009838369,0.0007792804,0.0009580896],"domain_scores_gemma":[0.9964612,0.001277822,0.000334582,0.0004426746,0.0009004393,0.0005833206],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7717799,0.000491057,0.0001110079,0.0003853261,0.0007173045,0.00004377728,0.001279403,0.00003861175,0.1544534,0.0000318434,0.0003532659,0.0703151],"study_design_scores_gemma":[0.8830426,0.005250326,0.001549376,0.00123008,0.0001809339,0.0000556044,0.001752978,0.0001513184,0.1041207,0.0001618708,0.002004489,0.000499758],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9651716,0.0103817,0.00001879299,0.006754782,0.0002477597,0.009096194,0.008210961,0.00009967046,0.00001854562],"genre_scores_gemma":[0.9804875,0.01249073,0.0002128876,0.0001288196,0.0009722258,0.004878792,0.0004580488,0.0001499391,0.0002210138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1112627,"threshold_uncertainty_score":0.9998264,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.076524905853375,"score_gpt":0.4258862522461008,"score_spread":0.3493613463927258,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}